Pipeline

March 29, 2020
Company Drug/Device Medical Condition Status
COVID-19 Trials and Actions
Genentech intravenous Actemra (tocilizumab) plus standard of care hospitalized adult patients with severe COVID-19 pneumonia initiation of phase 3 trial
Abbott RealTime SARS-CoV-2 EUA molecular tests SARS-CoV-2 approved by the FDA
Cepheid Xpert Xpress SARS-CoV-2 molecular diagnostic test SARS-CoV-2 approved by the FDA
Mesa Biotech Accula SARS-CoV-2 Test SARS-CoV-2 Emergency Use Authorization approved by the FDA
Bellerophon Therapeutics inhaled nitric oxide (iNO) delivery system, INOpulse SARS-CoV-2 emergency expanded access approved by the FDA
PerkinElmer Coronavirus RT-PCR test SARS-CoV-2 Emergency Use Authorization approved by the FDA
Quidel Corporation Lyra SARS-CoV-2 Assay SARS-CoV-2 Emergency Use Authorization approved by the FDA
Other Trials
Pliant Therapeutics PLN-1474 nonalcoholic steatohepatitis (NASH) with liver fibrosis dosing of first cohort in phase 1 trial
EOC Pharma eftilagimod alpha (IMP321) metastatic breast cancer completed patient enrollment in phase 1 trial
Allakos subcutaneous antolimab (AK002) healthy subjects initiation of phase 1 trial
Inflazome Inzomelid Cryopyrin-Associated Periodic Syndrome completion of phase 1 study
Ascentage Pharma APG-2575 in combination with rituximab or acalabrutinib relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma dosing of first subject in phase 1b/2 trial
Allakos antolimab (AK002) active, biopsy-confirmed eosinophilic esophagitis initiation of phase 2/3 trial
Allakos antolimab (AK002) active, biopsy confirmed eosinophilic gastritis and/or eosinophilic duodenitis initiation of phase 3 trial
Avadel Pharmaceuticals FT218 (once-nightly sodium oxybate) excessive daytime sleepiness and cataplexy in patients with narcolepsy completion of phase 3 trial
AgNovos Healthcare AGN1 Local Osteo-enhancement Procedure (LOEP) Small Volume (SV) Kit stable vertebral compression fractures Breakthrough Device designation granted by the FDA
Prevail Therapeutics PR006 to slow the progression of frontotemporal dementia with a GRN mutation (FTD-GRN) Fast-Track designation granted by the FDA
AEGEA Medical Mara Water Vapor Ablation System heavy menstrual bleeding approved by the FDA
Pfizer Eucrisa (crisaborole) ointment, 2% children 3 months of age and older with mild-to-moderate atopic dermatitis sNDA approved by the FDA

 

Upcoming Events

Featured Products

Featured Stories

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here